Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A2 | O43868 | 9/20 | 0.51 |
| ▸ | FBP1 | P09467 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | HSPA8 | P11142 | 5/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025801 | 0.90 | FBP1 (0.48) | SLC28A2FBP1ADORA2AADORA1HSPA8 | |
| SCHEMBL4022673 | 0.89 | FBP1 (0.48) | SLC28A2FBP1ADORA2AADORA1HSPA8 | |
| SCHEMBL4025797 | 0.89 | FBP1 (0.48) | SLC28A2FBP1ADORA2AADORA1HSPA8 | |
| SCHEMBL27708066 | 0.87 | SLC28A2 (0.49) | SLC28A2FBP1ADORA2AADORA1ADORA2B | |
| SCHEMBL4402903 | 0.87 | SLC28A2 (0.47) | SLC28A2FBP1ADORA2AADORA1HSPA8 | |
| SCHEMBL985660 | 0.83 | ADORA2A (0.51) | SLC28A2FBP1ADORA2AADORA1ADORA2B | |
| SCHEMBL985294 | 0.81 | ADORA2A (0.51) | FBP1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6762603 | 0.75 | SLC28A2 (0.83) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL15089829 | 0.73 | TMIGD3 (0.43) | ADORA2AADORA1ADORA2BMAPK1KDM4C | |
| SCHEMBL986123 | 0.73 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BADORA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115764-B | New macrolides | BASILEA PHARMACEUTICA AG | 2012-09-26 | — | — | CN | disclosed |
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| EP-1846430-B1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | SLC28A2 1570/4885FBP1 203/4885ADORA2A 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.